Table 1.

Gene/protein expression in tumor tissue homogenates measured by quantitative RT-PCR and Western blotting

SeriesGene expression by RT-PCR
Protein expression by Western blotting
HIF1AVHLP53HSP90BAXBCL2BAX/BCL2CASP3Pro-CASP9Active CASP9VEGF
Control53.1 ± 2.468.9 ± 3.234.8 ± 1.613.2 ± 0.818.1 ± 0.435.1 ± 1.10.51 ± 0.0239.9 ± 1.440.1 ± 1.70.56 ± 3.4842.0 ± 1.4
HIF1A ASO50.6 ± 3.165.3 ± 4.036.1 ± 3.312.6 ± 2.419.4 ± 2.136.6 ± 3.80.52 ± 0.0840.4 ± 3.641.2 ± 3.10.58 ± 4.0943.7 ± 4.1
Liposome53.9 ± 3.169.2 ± 3.734.3 ± 1.312.9 ± 1.118.2 ± 0.534.9 ± 1.30.52 ± 0.0238.9 ± 1.640.3 ± 1.90.5 ± 4.1341.9 ± 1.2
Liposomal HIF1A ASO34.4 ± 1.7*52.5 ± 2.7*48.4 ± 2.1*11.6 ± 1.817.8 ± 1.630.1 ± 1.4*0.60 ± 0.02*48.8 ± 2.0*50.2 ± 2.4*12.1 ± 0.8*35.4 ± 1.5*
Free doxorubicin89.7 ± 4.1*104.1 ± 5.3*62.5 ± 3.2*76.4 ± 3.3*58.0 ± 2.4*71.0 ± 2.9*0.82 ± 0.04*60.3 ± 2.9*74.5 ± 3.2*28.2 ± 0.9*136.1 ± 3.7*
Liposomal doxorubicin81.3 ± 4.6*86.0 ± 4.9*78.4 ± 2.6*58.6 ± 1.9*65.9 ± 2.4*54.2 ± 1.8*1.22 ± 0.05*81.1 ± 3.7*110.3 ± 4.1*39.1 ± 1.0*97.2 ± 3.4*
Liposomal doxorubicin + HIF1A ASO24.9 ± 1.7*70.2 ± 3.199.8 ± 4.1*28.2 ± 0.9*79.1 ± 3.0*36.7 ± 1.42.16 ± 0.09*113 ± 4.6*136.8 ± 4.3*54.3 ± 1.9*62.3 ± 2.6*
  • NOTE: The expression is presented as a percentage of the internal standard (β2-microglobilin and β-actin for RT-PCR and Western blotting, respectively). The samples for the analysis were taken at the end of the experiments (day 6 after the treatment; mean ± SD).

  • * P < 0.05 when compared with control.

  • P < 0.05 when compared with free doxorubicin.

  • P < 0.05 when compared with liposomal doxorubicin.